Molecular, Solid-State and Surface Structures of the Conformational Polymorphic Forms of Ritonavir in Relation to their Physicochemical Properties.
Ritonavir
conformation / packing energy balance
crystal morphology
inter-molecular packing
lattice energy
molecular conformational deformation energy
particle surface energy
solvent selection
surface chemistry
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
16
03
2021
accepted:
26
04
2021
pubmed:
20
5
2021
medline:
15
12
2021
entrez:
19
5
2021
Statut:
ppublish
Résumé
Application of multi-scale modelling workflows to characterise polymorphism in ritonavir with regard to its stability, bioavailability and processing. Molecular conformation, polarizability and stability are examined using quantum mechanics (QM). Intermolecular synthons, hydrogen bonding, crystal morphology and surface chemistry are modelled using empirical force fields. The form I conformation is more stable and polarized with more efficient intermolecular packing, lower void space and higher density, however its shielded hydroxyl is only a hydrogen bond donor. In contrast, the hydroxyl in the more open but less stable and polarized form II conformation is both a donor and acceptor resulting in stronger hydrogen bonding and a more stable crystal structure but one that is less dense. Both forms have strong 1D networks of hydrogen bonds and the differences in packing energies are partially offset in form II by its conformational deformation energy difference with respect to form I. The lattice energies converge at shorter distances for form I, consistent with its preferential crystallization at high supersaturation. Both forms exhibit a needle/lath-like crystal habit with slower growing hydrophobic side and faster growing hydrophilic capping habit faces with aspect ratios increasing from polar-protic, polar-aprotic and non-polar solvents, respectively. Surface energies are higher for form II than form I and increase with solvent polarity. The higher deformation, lattice and surface energies of form II are consistent with its lower solubility and hence bioavailability. Inter-relationship between molecular, solid-state and surface structures of the polymorphic forms of ritonavir are quantified in relation to their physical-chemical properties.
Identifiants
pubmed: 34009625
doi: 10.1007/s11095-021-03048-2
pii: 10.1007/s11095-021-03048-2
pmc: PMC8217055
doi:
Substances chimiques
HIV Protease Inhibitors
0
Ritonavir
O3J8G9O825
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
971-990Subventions
Organisme : AMSCI
ID : Grant No. 14060
Organisme : Engineering and Physical Sciences Research Council
ID : EP/I028293/1
Organisme : Engineering and Physical Sciences Research Council
ID : EP/IO14446/1
Organisme : Engineering and Physical Sciences Research Council
ID : EP/IO13563/1
Références
J Phys Chem B. 2005 Oct 27;109(42):19550-2
pubmed: 16853527
Pharm Dev Technol. 2005;10(2):291-7
pubmed: 15926678
Phys Chem Chem Phys. 2018 May 3;20(17):11622-11633
pubmed: 29662981
N Engl J Med. 1995 Dec 7;333(23):1534-9
pubmed: 7477168
Angew Chem Int Ed Engl. 2013 Feb 18;52(8):2166-79
pubmed: 23307268
J Phys Chem B. 2016 May 19;120(19):4331-40
pubmed: 27123749
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2180-4
pubmed: 12604798
J Chem Theory Comput. 2010 May 11;6(5):1509-19
pubmed: 26615687
Pharm Res. 2001 Jun;18(6):859-66
pubmed: 11474792
Faraday Discuss. 2015;179:79-114
pubmed: 25920721
J Pharm Sci. 2019 May;108(5):1655-1662
pubmed: 30615878
Phys Chem Chem Phys. 2008 Nov 28;10(44):6615-20
pubmed: 18989472
Acta Crystallogr B. 2002 Jun;58(Pt 3 Pt 1):380-8
pubmed: 12037359
J Pharm Sci. 2019 May;108(5):1779-1787
pubmed: 30590015
J Pharm Pharmacol. 2015 Jun;67(6):847-56
pubmed: 25880016
Pharm Res. 1995 Mar;12(3):413-20
pubmed: 7617530
Acta Crystallogr B Struct Sci Cryst Eng Mater. 2016 Apr;72(Pt 2):171-9
pubmed: 27048719
Mol Pharm. 2015 Jan 5;12(1):18-33
pubmed: 25380027
Lancet. 1998 Feb 21;351(9102):543-9
pubmed: 9492772
J Cheminform. 2018 Aug 29;10(1):44
pubmed: 30159699
Nat Commun. 2019 Jun 28;10(1):2893
pubmed: 31253797
J Pharm Sci. 2006 Nov;95(11):2361-72
pubmed: 16886182
J Control Release. 2017 Feb 28;248:71-95
pubmed: 28088572
Acta Crystallogr B. 2002 Jun;58(Pt 3 Pt 1):389-97
pubmed: 12037360
Int J Pharm. 2017 Oct 5;531(1):266-275
pubmed: 28843349